Gilli, Stefanie; Novak, Urban; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M.; Leibundgut, Kurt; Banz Wälti, Yara; Zander, Thilo; Betticher, Daniel; Egger, Thomas; Rauch, Daniel; Pabst, Thomas (2017). BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Annals of hematology, 96(3), pp. 421-429. Springer 10.1007/s00277-016-2900-y
|
Text
BM_GMB_BeEAM conditioning with bendamustine-replacing BCNU .pdf - Published Version Available under License Publisher holds Copyright. Download (388kB) | Preview |
BEAM with BCNU is commonly used for conditioning treatment followed by autologous stem cell transplantation (ASCT). However, pulmonary toxicity and availability issues associated with BCNU prompted us to evaluate bendamustine-replacing BCNU (BeEAM). We analyzed 39 lymphoma patients receiving BeEAM conditioning with 200 mg/m(2) bendamustine at days -7 and -6. The median duration until neutrophil recovery was 11 days, and 15 days for platelet recovery (>20 g/L). The most common grade 3/4 non-hematologic toxicities comprised mucosal side effects (27 pts.). Pulmonary toxicity was observed in one patient (2.5%), and one patient died of septic complications. The CR rate increased from 33% to 74% 100 days after ASCT. After a median follow-up of 18.5 months, progression and death each occurred in 11 patients (28%). Median progression-free and overall survival at 2 years were 69% and 72%. Our data suggest that BeEAM conditioning using bendamustine is safe and results in promising survival rates.
Actions (login required)
 |
Edit item |